Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. by Barosi, G. et al.
British Journal of Cancer (1998) 78(6), 781-787
© 1998 Cancer Research Campaign
Cost-effectiveness of recombinant human erythropoietin
in the prevention of chemotherapy-induced anaemia
G Barosi, M Marchetti and NL Liberato
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Summary Recombinant human erythropoietin (rHuEPO) has been advocated for the treatment of anaemia in patients submitted to cancer
chemotherapy. We used decision analysis to compare the cost-effectiveness of rHuEPO supplemented with red blood cell (RBC) transfusions
with conventional treatment with RBC transfusions alone. At baseline, we analysed the use of rHuEPO as secondary prophylaxis according
to effectiveness estimates from a community-based oncology study. In order to reduce the probability of transfusions from 21.9% to 10.4%,
and the number of RBC units per patient per month from 0.55 to 0.29, 150 units kg-' s.c. rHuEPO three times per week for 4 months resulted
in an incremental cost of $189 652 per quality-adjusted life year (QALY). In patients treated with cisplatin-containing chemotherapy, rHuEPO
added $190 142 per QALY. In a hypothetical scenario of a transfusion pattern that maintained the same haemoglobin level of rHuEPO-
responsive patients, the marginal cost of rHuEPO was always greater than $100 000 per QALY. Results were stable with regard to variations
in the probability of blood-borne infections, quality of life of responding patients and cancer-related mortality. The additional cost could be
lowered to less than $100 000 per QALY by saving 4.5 RBC units over 4 months for any patient treated. In conclusion, according to current
use, rHuEPO is not cost-effective in the treatment of chemotherapy-induced anaemia. More tailored utilization of the drug and better
consideration of predictive response indicators may lead to an effective, blood-sparing alternative.
Keywords: recombinant human erythropoietin; cost-effectiveness analysis; chemotherapy-induced anaemia; decision analysis; cisplatin-
containing chemotherapy
Anaemia is a frequent complication in patients with cancer
receiving cytotoxic chemotherapy. It impairs patients' physical
capabilities and subjective sense of well-being, diminishing their
quality of life. In controlled randomized studies, rHuEPO was
associated with increased haemoglobin level, decreased transfu-
sion requirements and improved quality oflife (Abels, 1993; Case
et al, 1993; Finelli et al, 1993; Cascinu et al, 1994; Henry and
Abels, 1994; Cazzola et al, 1995; De Campos et al, 1995; Garton
et al, 1995; Oesterborg et al, 1996; ten Bokkel-Huinink, 1996;
Wurnig et al, 1996; Del Mastro et al, 1997). As the same results
were obtained in a community oncology practice setting (Glaspy
et al, 1997), recommendations for rHuEPO use and a treatment
algorithm for its optimization were outlined (Glaspy et al, 1997).
In contrast, because of increasing financial constraints
throughout health care systems, the amount ofmoney allotted for a
new treatment has to be considered in relation to the magnitude of
the benefit offered with respect to traditional therapy. As a conse-
quence, cost-effectiveness analysis belongs to the development
process aimed at establishing policy for drug use. The purpose of
this work is to provide a cost-effectiveness analysis ofrHuEPO in
the chemotherapy-induced anaemia ofcancer.
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METHODS
Base case
As the best strategy for administering rHuEPO to patients under-
going cancer chemotherapy has not yet been determined, at base-
line we modelled the most resource-saving treatment strategy, i.e.
the use ofthe drug for secondary prophylaxis, reserved for patients
who had developed severe anaemia as a consequence of
chemotherapy. The case upon which this analysis is based was
derived from the results of a community-based US multicentre
oncology study (Glaspy et al, 1997). As such, a hypothetical
typical patient fulfilling the criteria for therapy receives treatment
at a mean age of 65 years, does not carry any other cause for
anaemia except cancer chemotherapy, always has an expected
survival of more than 6 months and is treated with rHuEPO when
haemoglobin falls below 10.7 g dl-'. To better reflect the health
care system perspective, we assumed that both rHuEPO and RBC
transfusions were administered in the hospital. We outlined our
model on the basis of a 4-month course of rHuEPO with doses of
150 units kg-' three times per week, i.e. according to the protocol
providing treatment guidance for patients in the community
setting.
The decision model
The model (developed using DATA software forWindows, Tree Age
Software, Boston, MA, USA) evaluated two clinical management
strategies: experimental prophylactic use of rHuEPO supplemented
with RBC transfusions and conventional treatment with RBC
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transfusions alone (Figure 1). In both strategies, patients were subdi-
vided according to their chance of being transfused during the
following 4 months of chemotherapy. In the strategy of employing
rHuEPO, the model depicted the chance of response, i.e. of
increasing haemoglobin level by more than 2 g dl-I with respect to
the baseline value. This outcome was considered to change the
quality of life of these patients. Even though the general policy of
oncological institutions is not to administer RBC transfusions unless
the haemoglobin level drops below 8 g dl' (Glaspy et al, 1997), in
the strategy of transfusions alone we modelled a response similar to
that in the rHuEPO arm. In the baseline analysis, transfusions were
considered to be palliative and not to increase haemoglobin levels or
change the patients' quality oflife. A hypothetical transfusion pattern
that approximates to haemoglobin response obtained with a
successful rHuEPO therapy was outlined in the scenario analysis.
With both strategies, patients receiving transfusions were at risk
for acute or long-standing adverse effects. The risk was that of a
single RBC unit multiplied by the number of units transfused.
Transfusion reactions contributed only their costs, whereas blood-
borne infections due to hepatitis C virus (HCV) and human
immunodeficiency virus (HIV) carried mortality, morbidity and
costs. Their outcomes were explicitly outlined in the model.
Following HCV infection, a proportion of patients die of acute
hepatitis. Later, there is a low sequential progression from acute
viral infection to chronic hepatitis, cirrhosis and, eventually, hepato-
cellular carcinoma. Hepatitis B virus (HBV), cytomegalovirus
(CMV) or human T-cell lymphotrophic virus (HTLV) infections
were cumulatively considered for their chance to develop post-
transfusional adverse events, and were considered to contribute only
to costs. As a matter of fact, although the acquisition of hepatitis B
virus through transfusions is reported to be from I in 3300
(Donahue et al, 1992) to 1 in 63 000 (Schreiber et al, 1996), the
probability of developing acute or chronic hepatitis B is nearly null
(Blajchman et al, 1995); donor antibody screening and/or the use of
white cell reduction filters have virtually eliminated cytomegalo-
virus infections (Dodd, 1992), and human T-cell lymphotrophic
virus strain I or 2 is reported to infect I in 641 000 without mortality
(Schreiber et al, 1996). Each decision pathway ends with a terminal
node related to its utility. We framed utility on two different dimen-
sions: the cost of the health care resources used and the quality-
adjusted life expectancy for the various health states.
We defined the incremental cost-effectiveness of secondary
prophylaxis with rHuEPO as the net change in the amount of
health care resources required to administer the drug, as opposed
to not administering it, divided by the net change in the amount of
health benefits resulting from this substitution.
To determine the stability of our results and to gauge the effect
of uncertainty in the values we assigned to the variables, these
point values were analysed over a range of values in a process
known as sensitivity analysis.
Because benefits and costs were assumed to occur in the future,
their future value was discounted at a rate of3% per year to estimate
present value, as is consistent with conventional practice (Task Force
on Principles for Economic Analysis of Health Care Technology,
1995). The cost values derived from literature were standardized to
the present year by considering a yearly inflation rate of5%.
Scenario analysis
Scenario analysis allows one to examine how the optimality of
a strategy will be affected by conceivable changes in structural
assumptions. In a scenario analysis, we considered cisplatin-
containing chemotherapy-treated patients, i.e. the cytotoxic
therapy with the highest probability of severe anaemia, but also the
one with the best response rate to rHuEPO. A hypothetical
scenario was devised to simulate the transfusion pattern that would
be necessary to approximate to the maintained haemoglobin
response seen with rHuEPO. Patients developing anaemia during
chemotherapy were assumed to receive transfusions to increase
the baseline haemoglobin value by more than 2 g dl-1.
Assumptions
In an economic analysis of rHuEPO use in patients with the
anaemia of cancer, some assumptions can be made.
1. Side-effects from rHuEPO therapy like hypertension and
thrombosis, which are not rare in end-stage renal disease but
are rare in cancer patients, need not be considered.
2. The cost of both iron replacement during rHuEPO and of iron
chelation during transfusion therapy is usually small compared
with overall treatment cost in renal anaemia (Leese et al,
1992), and even smaller in the anaemia of cancer because of
the shorter treatment time.
3. The immunomodulating effects of allogeneic transfusions need
not be considered, because current evidence for these effects
comes primarily from retrospective studies.
4. Loss of productivity, which is an indirect cost of transfusion
administration, is negligible because rHuEPO therapy is
employed only during severe disease phases when the patient
is out of work.
5. The possible long-term effects of transfusional therapy caused
by blood-borne infections can be weighted against the limited
duration of life expectancy for cancer. In baseline analysis, we
assumed a mean life expectancy of 5 years for these patients.
This assumption was chosen operatively and its impact on the
cost-effectiveness results was examined by sensitivity
analysis.
Data on effectiveness
The probabilities of the model outcomes were estimated by
sources identified through repeated computer searches of the
Medline medical literature and from the reference list of relevant
papers. When assumptions or estimates were equivocal, we
assigned values that tended to bias our results in favour of
rHuEPO.
Response to rHuEPO treatment
Baseline data on the effectiveness of secondary prophylaxis for
anaemia with rHuEPO in patients with any form of cancer were
derived from the largest study on community-based oncologists
(Glaspy et al, 1997) and are reported in Table 1. These values were
within the range of the data from randomized clinical trials on
secondary prophylaxis (Abels, 1993; Cascinu et al, 1994; Wurnig
et al, 1996). The best estimates from randomized clinical trials
were: for probability of transfusion, 56% in placebo and 20% in
rHuEPO-treated patients; and for transfusion load, 1.8 units per
month in placebo and 0.30 in treated patients. These values were
used in the sensitivity analysis.
For cisplatin-treated patients, the estimated average rHuEPO
response rate was derived from a prospective, randomized,
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Table 1 Probabilities of outcomes used in the analysis
Outcome Value
Patients treated with any chemotherapy (from Glaspy etal, 1997)
With rHuEPO
Probability of transfusions (%)
Units of RBC per month
Probability of improvement of anaemia in non-transfused patients (%)
Probability of improvement of anaemia in transfused patients (%)
Without rHuEPO
Probability of transfusions (%)
Units of RBC per month
Patients treated with cisplatin-containing chemotherapy (from Abels et al, 1993)
With rHuEPO
Probability of transfusions (%)
Units of RBC per month
Probability of improvement of anaemia (%)
Without rHuEPO
Probability of transfusions (%)
Units of RBC per month
double-blind, placebo-controlled trial with a cumulative sample
size of 125 patients (Abels et al, 1993).
In the scenario of transfusion policy aimed at approximating to
the haemoglobin response seen with rHuEPO, the average trans-
fusion requirement was set at 2 units per month, as reported in
patients with renal anaemia to maintain a sustained haemoglobin
level (Scheingold et al, 1992).
Risk ofblood-borne infections
The overall per unit rate of post-transfusion diseases is reported in
Table 2. The 0.4 per 1000 incidence of HCV hepatitis was derived
from a study on patients receiving allogeneic blood after HCV
screening in Canada (Blajchman et al, 1995), and was quite similar
to the 3 per 10 000 transfused units reported in patients receiving
blood between 1985 and 1991 in the United States (Donahue et al,
1992). The post-hepatitis outcomes were derived from a prospec-
tive, population-based study (Tong et al, 1995). The annual inci-
dence rates of chronic hepatitis, liver cirrhosis, liver carcinoma
and hepatitis-associated deaths were calculated from the total inci-
dence rate and the number ofpatient-years offollow-up. This was
obtained by assuming that in that study all the patients with serious
liver disease related to post-transfusion HCV in the reference
population had been observed, and that the risk ofdeveloping liver
diseases had a normal distribution over time. The final results were
similar to other data in the literature. The 20% rate of clinical
evidence ofcirrhosis in patients with HCV infection 16 years after
the initial blood transfusion (Koretz et al, 1993) was quite similar
to the cumulative rate of 21.1% we calculated. The results were,
however, in disagreement with other studies that reported that very
few patients showed complications of chronic infection after an
average follow-up of 18 years (Seeff et al, 1992). The percentage
of liver-related mortality (0.59% per year) was higher than the
mortality in other long-term, prospective cohort studies (Koretz et
al, 1985; Alter et al, 1988) that described a mortality of0.35% per
year: however, in these latter studies the follow-up was shorter
than in our reference study.
The per unit probability of HIV infection in donated allogeneic
blood was derived from the most recent survey of donors who
10.4
0.29
57.7
31.1
21.9
0.55
53.1
1.16
48.4
68.9
1.34
gave blood between 1991 and 1993 (Schreiber et al, 1996). The
figure ascertained of 1 in 493 000 was in the range of values esti-
mated from demographic and laboratory data on more than 4.1
million blood donations made in 1992 and 1993 in the US; a risk
of one case of HIV transmission for every 450 000-660 000 dona-
tions of screened blood (Lackritz et al, 1996) was estimated.
Costs
The relative costs fall into three categories: the cost of rHuEPO
therapy, the cost of blood transfusions and the cost of treating the
adverse effects related to transfusions. All cost values are
expressed in US dollars.
Cost ofrHuEPO
The costs attributable to rHuEPO include that ofthe drug itself, the
pharmacy expenses and the nursing cost ofadministering it a total
of 48 times over 16 weeks. In Italy, the drug is sold to the phar-
macy at half-price: 1000 U of the drug costs approximately $10.
The cost for supplies (needles, syringes, alcohol wipes, etc.) and
for preparations to administer each dose ofrHuEPO was estimated
to be $2.50. Throughout the study, no drug wastage was consid-
ered, i.e. all of the rHuEPO in a vial is administered. During the
study, we have considered a baseline cost of $4440 for the 4
months oftherapy, i.e. the cost for a 60 kg man.
Cost of transfusions
Because the real cost of blood transfusions varies from centre to
centre, we decided it would be unreliable to determine this amount
with data from a single institution. The estimated average direct
cost ofone allogeneic blood unit ranges from $149.80 (Etchason et
al, 1995) to $422 (Mohandas and Aledort, 1995). To bias our
results in favour of rHuEPO, we considered the baseline unit cost
to be $422. A breakdown of this estimate includes blood collec-
tion, infectious disease testing, blood processing, inventory
management and compatibility testing.
The cost of treating transfusion-related complications was
derived from a recent estimate (Wong et al, 1995). According to
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Table 2 Risk of blood-borne infections
Event Event rate (%) Reference
Post-transfusion HCV hepatitis 0.004 Blajchman et al (1995)
Death from acute hepatitis 2.5 Birkmeier et al (1993)
Chronic persistent hepatitis (per year) 0.93 Tong et al (1995)
Chronic active hepatitis (per year) 1.04 Tong et al (1995)
Cirrhosis (per year) 1.32 Tong et al (1995)
Hepatocarcinoma (per year) 0.24 Tong et al (1995)
Death (per year) 0.59 Tong et al (1995)
Table 3 Adjustment for quality of life used in the model
Quality of life Quality-adjustment factor
Patients treated with any chemotherapy (from Glaspy etal, 1997)
Basal value 0.47
After anaemia correction with rHuEPO 0.61
Patients treated with cisplatin-containing chemotherapy (from Abels etal, 1992)
Basal value 0.50
After anaemia correction with rHuEPO 0.74
Blood-bome diseases (from Wong etal, 1995)
Chronic active hepatitis 0.94
Cirrhosis 0.80
Hepatocellular carcinoma 0.50
HIV infection 0.75
this source, treating transfusion-associated hepatitis added $4.05
to the cost ofeach allogeneic blood unit, while treating HIV infec-
tion added another $0.63 per allogeneic unit. Taken together, trans-
fusion-related complications added $4.68 to the price ofeach unit
of blood. Adding this indirect expense to the direct cost of $422
yielded a total of $426.70 per transfused allogeneic blood unit.
This figure is approximately double the $210 total cost calculated
for transfusions performed on an in-patient basis in Canada, which
included personnel, purchases, external services, overhead,
donors' time, wastage and infection (Tretiak et al, 1996) This
amount is also higher than the mean cost of transfusion in Italy,
which was estimated to be approximately $250 (F Mercuriali,
personal comunication).
Quality of life adjustment
Quality of life (QOL) adjustment included explicit considerations
of the degree to which disease states diminish the well-being of
patients. At baseline, we used the overall QOL score, provided on
a visual analogue scale by the patients in the community oncology
setting, which measures separately the effect ofthe amelioration of
anaemia and that of tumour response (Glaspy, 1997). The QOL of
cancer patients was low at baseline - 46.8 on a scale from 0 to 100
- and the net improvement in QOL due to amelioration ofanaemia
was 14.4. The same QOL improvement was used also for patients
heavily transfused so as to reach the same haemoglobin level of
rHuEPO responding patients. In cisplatin-treated patients (Abels
et al, 1992), the QOL score rose from 50 to 74 in rHuEPO respon-
ders. Adjustments for the QOL related to post-transfusional
hepatitis and HIV infection were derived from the literature (Table
3). Chronic disease states were assigned a quality adjustment
factor from 0.50 to 0.94, meaning that a year oflife with the symp-
toms ofhepatitis or HIV complications was considered to be worth
only a corresponding fraction of a year oflife without them.
RESULTS
In the baseline analysis, saving RBC transfusions by rHuEPO
administration increases quality-adjusted life expectancy by 8.4
days. However, the average cost ofadding rHuEPO to transfusions
($4568) was $4362 greater than that of RBC transfusions alone
($206), corresponding to an incremental cost-effectiveness of
$189 652 per quality-adjusted life-year (QALY).
In sensitivity analysis, transfusion therapy alone remained the
most cost-effective strategy, even with a risk ofblood-borne infec-
tions up to double the mean values reported in the literature. For
these latter values, rHuEPO still adds more than $100 000 to the
cost per QALY gained. We next analysed changes in the efficacy
ofrHuEPO assuming a normal life expectancy for cancer patients.
Even with this highly favourable assumption, the marginal cost-
effectiveness of rHuEPO was high: rHuEPO would mean more
than an additional $100 000 per quality-adjusted life year in both a
65- and a 25-year-old patient. The results were insensitive to other
uncertain variables. A 30% increase in the QOL of responding
patients did not alter the qualitative results of our analysis;
rHuEPO would cost an additional $145 400 per quality-adjusted
life year.
The model variables that significantly modified the results were
the price and the efficacy ofrHuEPO. The incremental cost-effec-
tiveness dropped below $100 000 per QALY gained, only at a drug
cost of $2250 per 4 months of treatment, i.e. when the price was
reduced to 50% of its basal value. Increasing the efficacy of
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Figure 1 (A) Decision tree for a cost-effectiveness analysis of rHuEPO with respect to transfusional therapy. The starting point of the decision is shown by the
squared node on the left. The round nodes indicate chance events. On the far right of the tree, the strategies end with utility nodes (triangles) bearing the
dimensions of cost and quality-adjusted life-expectancy. (B) Subtree representing the transfusion-related outcomes, in which HCV hepatitis and HIV infection
are explicitly outlined
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Figure 2 Marginal cost-effectiveness of rHuEPO compared with transfusion
alone, in relation to the number of units of red blood cell transfusions avoided
with rHuEPO therapy and the cost of rHuEPO for 4 months of therapy. The
baseline cost of the drug is $4440
rHuEPO treatment had a substantial impact on the marginal cost-
effectiveness only in a treatment scenario that remains far from
what is presently reported. In fact, even if the drug were able to
abolish the need for transfusions in all patients receiving
chemotherapy and improve anaemia in all rHuEPO-treated
patients, the marginal cost-effectiveness would be still high, i.e.
$146 040 per QALY gained. As shown in Figure 2, at the current
price of use, i.e. more than $4 000 for the 4 months of treatment,
rHuEPO would cost less than an additional $100 000 per QALY if
the drug were administered only to patients who were heavily
transfused during chemotherapy (more than 4.5 units ofRBC for 4
months), and if it succeeded in abolishing their transfusion need.
Only at half the price ($2000 for 4 months oftherapy) is the drug
cost-effective at any reduction in the transfusion need.
In the scenario of patients treated with cisplatin-containing
chemotherapy, the use ofrHuEPO would add $190 142 per QALY.
Increasing the transfusion load so as to improve the QOL as well
as rHuEPO dose would increase the transfusion cost by 30%. The
incremental cost-utility with respect to rHuEPO, however, is $172
928 per QALY.
DISCUSSION
Although current blood transfusion regimens are effective in
avoiding severe anaemia in patients treated with cytotoxic
chemotherapy for cancer, concerns about the risk of late blood-
borne infections and claims of improved quality of life have led
researchers to consider alternative treatment with rHuEPO. In the
present study, we modelled the use of rHuEPO as secondary
prophylaxis in chemotherapy-related anaemia, i.e. in only approx-
imately 50% of the patients (Del Mastro et al, 1994) who develop
severe anaemia during chemotherapy. With this treatment
modality, rHuEPO does not completely eliminate the need for
blood transfusions; in fact, 10-29% of anaemic patients still have
British Journal of Cancer (1998) 78(6), 781-787
Ad
AL,
AL,
AL,
Al&
A&
I
AL
a)
c -
a) '
o 0
o .cm- 0)u- is
-------------0
0 Cancer Research Campaign 1998786 G Barosi et al
to be transfused despite treatment (Case et al, 1993; Cascinu et al,
1994; Henry et al, 1994; Wurning et al, 1996; Glaspy et al, 1997).
Our analysis of treatment with rHuEPO as compared with blood
transfusion alone shows that, at the current response rate, every
QALY gained costs approximately $190 000. Compared with
other forms of clinical therapy, rHuEPO in the anaemia of
chemotherapy is a highly expensive tool. To achieve one QALY
with rHuEPO for the anaemia of end-stage renal disease, for
instance, costs approximately $20 000 (Nicholls, 1992), i.e. more
than nine times cheaper. Moreover, this figure is well above the
estimated cost per QALY for a number of other health care
therapies (Maynard, 1991).
This is true even when a particularly high cost for a RBC trans-
fusion unit is adopted in the baseline model, and when values
highly favourable to rHuEPO are set in the sensitivity analysis,
such as the incidence oftransfusion-related diseases, improvement
in the patient's QOL after improvement of anaemia and life
expectancy for cancer patients. As both the type of cancer and the
type of chemotherapy influence the effectiveness of rHuEPO, our
analysis included an alternative scenario which considered
patients treated with cisplatin-containing chemotherapy. At the
current efficacy of rHuEPO, the proportion of patients under the
drug who continue to be transfused is so high that the cost-
effectiveness ratio was greater than $100 000 per QALY.
The above-reported results are in agreement with a previously
published cost analysis of rHuEPO in cancer chemotherapy. In a
cost comparison ofrHuEPO vs leucocyte-depleted RBC transfusion
therapy, with a response rate of 64% with rHuEPO, full cost of the
drug and 8 months oftherapy, RBC transfusion resulted in a saving
of $8490 per patient (Sheffield et al, 1997). In a cost-effectiveness
analysis that considered a longer duration for therapy and efficacy
data from clinical trials (Barosi and Liberato, 1995), the baseline
cost-effectiveness ratio was more than $100 000 per QALY.
An alternative way to reduce the need for blood transfusions in
cancer patients under chemotherapy might be to use rHuEPO in
primary prophylaxis, i.e. in patients with normal or only slightly
reduced haemoglobin values before any chemotherapy is started.
A recent analysis of this modality (Del Mastro et al, 1997) docu-
mented that throughout six cycles of chemotherapy non-rHuEPO-
treated patients developed anaemia, but only 2 out of 31 of them
needed RBC transfusions. Given the higher cost component of
RBC transfusions avoided, as shown by the present analysis, this
strategy would be more expensive and less cost-effective than
secondary prophylaxis.
At baseline, the results of this study portray the use of transfu-
sions and of rHuEPO as derived from a community-based survey.
However, one could comment that, to obtain a more reasonable
comparison, the costs of rHuEPO need to be compared with the
costs which would be incurred if sufficient blood transfusion was
used to mimic the steady haemoglobin level achieved with
rHuEPO in patients who respond to the therapy. This calculation
was made in a scenario analysis. Using the increased level of
blood transfusion estimated to give a similar outcome to rHuEPO
therapy, the costs of managing these patients is still more than
$100 000 per QALY.
Economic analysis of medical technology is a useful tool for
focusing on ways to utilize the technology more rationally. Our
analysis pointed out that the greatest challenge to cost-effective
use of rHuEPO is to improve the drug's power to reduce the
number of units of blood transfused. This points at improving
response predictability. An inadequate serum erythropoietin level
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before therapy (Cazzola et al, 1995) and a serum erythropoietin
level lower than 100 mU ml-' associated with a haemoglobin
concentration increased by at least 0.5 g dl-' after 2 weeks of
therapy (Ludwig et al, 1994) have both been reported to predict
responsiveness. A narrower target for rHuEPO therapy can be
clinically implemented and studied as an effective blood-sparing
alternative. A prospective trial on the use of rHuEPO limited to
patients who have the characteristics that predict the response to
the drug is warranted. In that trial, besides health outcomes, the
economic component should be measured.
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